Deutsche Bank Aktiengesellschaft Initiates Coverage on Sarepta Therapeutics (NASDAQ:SRPT)

Equities research analysts at Deutsche Bank Aktiengesellschaft assumed coverage on shares of Sarepta Therapeutics (NASDAQ:SRPT) in a research report issued on Tuesday, MarketBeat reports. The firm set a “hold” rating and a $136.00 price target on the biotechnology company’s stock. Deutsche Bank Aktiengesellschaft’s price objective points to a potential upside of 23.85% from the stock’s previous close.

SRPT has been the topic of several other research reports. Robert W. Baird reduced their price target on shares of Sarepta Therapeutics from $200.00 to $193.00 and set an “outperform” rating on the stock in a research report on Thursday, November 7th. HC Wainwright reiterated a “sell” rating and set a $75.00 price target on shares of Sarepta Therapeutics in a research report on Thursday, January 30th. Cantor Fitzgerald upgraded shares of Sarepta Therapeutics from a “neutral” rating to an “overweight” rating and boosted their price target for the company from $152.00 to $167.00 in a research report on Thursday, November 7th. Guggenheim boosted their price target on shares of Sarepta Therapeutics from $148.00 to $150.00 and gave the company a “buy” rating in a research report on Thursday, November 7th. Finally, StockNews.com cut shares of Sarepta Therapeutics from a “buy” rating to a “hold” rating in a research report on Wednesday, November 20th. One research analyst has rated the stock with a sell rating, three have given a hold rating, nineteen have issued a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average price target of $176.77.

Sarepta Therapeutics Price Performance

SRPT stock opened at $109.81 on Tuesday. The firm’s 50-day moving average price is $120.16 and its two-hundred day moving average price is $125.22. Sarepta Therapeutics has a 12-month low of $102.15 and a 12-month high of $173.25. The stock has a market capitalization of $10.49 billion, a price-to-earnings ratio of 87.85 and a beta of 0.75. The company has a current ratio of 3.84, a quick ratio of 3.03 and a debt-to-equity ratio of 0.93.

Insider Transactions at Sarepta Therapeutics

In related news, Director Kathryn Jean Boor sold 1,636 shares of the stock in a transaction that occurred on Thursday, December 5th. The shares were sold at an average price of $125.55, for a total transaction of $205,399.80. Following the transaction, the director now owns 5,880 shares in the company, valued at $738,234. This represents a 21.77 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Hans Lennart Rudolf Wigzell sold 10,500 shares of the stock in a transaction that occurred on Thursday, December 12th. The shares were sold at an average price of $124.84, for a total transaction of $1,310,820.00. Following the transaction, the director now owns 22,840 shares in the company, valued at approximately $2,851,345.60. This trade represents a 31.49 % decrease in their position. The disclosure for this sale can be found here. Insiders own 7.70% of the company’s stock.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Vanguard Group Inc. increased its holdings in Sarepta Therapeutics by 1.3% during the fourth quarter. Vanguard Group Inc. now owns 9,085,456 shares of the biotechnology company’s stock valued at $1,104,701,000 after buying an additional 117,904 shares during the last quarter. Janus Henderson Group PLC increased its holdings in Sarepta Therapeutics by 14.2% during the third quarter. Janus Henderson Group PLC now owns 4,358,511 shares of the biotechnology company’s stock valued at $544,408,000 after buying an additional 543,143 shares during the last quarter. Wellington Management Group LLP increased its holdings in Sarepta Therapeutics by 32.3% during the third quarter. Wellington Management Group LLP now owns 2,726,613 shares of the biotechnology company’s stock valued at $340,527,000 after buying an additional 665,087 shares during the last quarter. Geode Capital Management LLC increased its holdings in Sarepta Therapeutics by 0.6% during the fourth quarter. Geode Capital Management LLC now owns 1,706,353 shares of the biotechnology company’s stock valued at $207,538,000 after buying an additional 9,999 shares during the last quarter. Finally, Norges Bank purchased a new stake in Sarepta Therapeutics during the fourth quarter valued at approximately $126,315,000. Institutional investors own 86.68% of the company’s stock.

Sarepta Therapeutics Company Profile

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.